74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
PROCEPT BioRobotics Corp
Closed
SectorHealthcare
52.59 -5.6
Overview
Share price change
24h
Min
50.05
Max
55.19
Income | 2.1M -19M |
|---|---|
Sales | 9.9M 68M |
EPS | -0.35 |
Profit margin | -27.634 |
Employees | 756 |
EBITDA | 2.1M -16M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +61.97% upside |
Market Cap | -596M 2.9B |
|---|---|
Previous open | 58.19 |
Previous close | 52.59 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
PROCEPT BioRobotics Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
PROCEPT BioRobotics Corp Forecast
Price Target
By TipRanks
61.97% upside
12 Months Forecast
Average 90.22 USD 61.97%
High 105 USD
Low 70 USD
Based on 11 Wall Street analysts offering 12 month price targets forPROCEPT BioRobotics Corp - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About PROCEPT BioRobotics Corp
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
